306 related articles for article (PubMed ID: 17133211)
1. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals.
Markowitz M; Morales-Ramirez JO; Nguyen BY; Kovacs CM; Steigbigel RT; Cooper DA; Liporace R; Schwartz R; Isaacs R; Gilde LR; Wenning L; Zhao J; Teppler H
J Acquir Immune Defic Syndr; 2006 Dec; 43(5):509-15. PubMed ID: 17133211
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial.
Grinsztejn B; Nguyen BY; Katlama C; Gatell JM; Lazzarin A; Vittecoq D; Gonzalez CJ; Chen J; Harvey CM; Isaacs RD;
Lancet; 2007 Apr; 369(9569):1261-1269. PubMed ID: 17434401
[TBL] [Abstract][Full Text] [Related]
3. Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study.
Markowitz M; Nguyen BY; Gotuzzo E; Mendo F; Ratanasuwan W; Kovacs C; Prada G; Morales-Ramirez JO; Crumpacker CS; Isaacs RD; Gilde LR; Wan H; Miller MD; Wenning LA; Teppler H;
J Acquir Immune Defic Syndr; 2007 Oct; 46(2):125-33. PubMed ID: 17721395
[TBL] [Abstract][Full Text] [Related]
4. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.
Cahn P; Pozniak AL; Mingrone H; Shuldyakov A; Brites C; Andrade-Villanueva JF; Richmond G; Buendia CB; Fourie J; Ramgopal M; Hagins D; Felizarta F; Madruga J; Reuter T; Newman T; Small CB; Lombaard J; Grinsztejn B; Dorey D; Underwood M; Griffith S; Min S;
Lancet; 2013 Aug; 382(9893):700-8. PubMed ID: 23830355
[TBL] [Abstract][Full Text] [Related]
5. Raltegravir.
Croxtall JD; Lyseng-Williamson KA; Perry CM
Drugs; 2008; 68(1):131-8. PubMed ID: 18081377
[TBL] [Abstract][Full Text] [Related]
6. Antiviral Activity, Safety, and Pharmacokinetics of Bictegravir as 10-Day Monotherapy in HIV-1-Infected Adults.
Gallant JE; Thompson M; DeJesus E; Voskuhl GW; Wei X; Zhang H; White K; Cheng A; Quirk E; Martin H
J Acquir Immune Defic Syndr; 2017 May; 75(1):61-66. PubMed ID: 28196003
[TBL] [Abstract][Full Text] [Related]
7. Raltegravir with optimized background therapy for resistant HIV-1 infection.
Steigbigel RT; Cooper DA; Kumar PN; Eron JE; Schechter M; Markowitz M; Loutfy MR; Lennox JL; Gatell JM; Rockstroh JK; Katlama C; Yeni P; Lazzarin A; Clotet B; Zhao J; Chen J; Ryan DM; Rhodes RR; Killar JA; Gilde LR; Strohmaier KM; Meibohm AR; Miller MD; Hazuda DJ; Nessly ML; DiNubile MJ; Isaacs RD; Nguyen BY; Teppler H;
N Engl J Med; 2008 Jul; 359(4):339-54. PubMed ID: 18650512
[TBL] [Abstract][Full Text] [Related]
8. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study.
Raffi F; Rachlis A; Stellbrink HJ; Hardy WD; Torti C; Orkin C; Bloch M; Podzamczer D; Pokrovsky V; Pulido F; Almond S; Margolis D; Brennan C; Min S;
Lancet; 2013 Mar; 381(9868):735-43. PubMed ID: 23306000
[TBL] [Abstract][Full Text] [Related]
9. Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.
Iwamoto M; Wenning LA; Petry AS; Laethem M; De Smet M; Kost JT; Merschman SA; Strohmaier KM; Ramael S; Lasseter KC; Stone JA; Gottesdiener KM; Wagner JA
Clin Pharmacol Ther; 2008 Feb; 83(2):293-9. PubMed ID: 17713476
[TBL] [Abstract][Full Text] [Related]
10. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.
Cooper DA; Steigbigel RT; Gatell JM; Rockstroh JK; Katlama C; Yeni P; Lazzarin A; Clotet B; Kumar PN; Eron JE; Schechter M; Markowitz M; Loutfy MR; Lennox JL; Zhao J; Chen J; Ryan DM; Rhodes RR; Killar JA; Gilde LR; Strohmaier KM; Meibohm AR; Miller MD; Hazuda DJ; Nessly ML; DiNubile MJ; Isaacs RD; Teppler H; Nguyen BY;
N Engl J Med; 2008 Jul; 359(4):355-65. PubMed ID: 18650513
[TBL] [Abstract][Full Text] [Related]
11. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients.
DeJesus E; Berger D; Markowitz M; Cohen C; Hawkins T; Ruane P; Elion R; Farthing C; Zhong L; Cheng AK; McColl D; Kearney BP;
J Acquir Immune Defic Syndr; 2006 Sep; 43(1):1-5. PubMed ID: 16936557
[TBL] [Abstract][Full Text] [Related]
12. Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase.
Murray JM; Emery S; Kelleher AD; Law M; Chen J; Hazuda DJ; Nguyen BY; Teppler H; Cooper DA
AIDS; 2007 Nov; 21(17):2315-21. PubMed ID: 18090280
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of and short-term virologic response to low-dose 400-milligram once-daily raltegravir maintenance therapy.
Ananworanich J; Gorowara M; Avihingsanon A; Kerr SJ; van Heesch N; Khongpetch C; Uanithirat A; Hill A; Ruxrungtham K; Burger DM;
Antimicrob Agents Chemother; 2012 Apr; 56(4):1892-8. PubMed ID: 22252825
[TBL] [Abstract][Full Text] [Related]
14. Raltegravir: in treatment-naive patients with HIV-1 infection.
Croxtall JD; Scott LJ
Drugs; 2010 Mar; 70(5):631-42. PubMed ID: 20329808
[TBL] [Abstract][Full Text] [Related]
15. Raltegravir: an integrase inhibitor for HIV-1.
Evering TH; Markowitz M
Expert Opin Investig Drugs; 2008 Mar; 17(3):413-22. PubMed ID: 18321239
[TBL] [Abstract][Full Text] [Related]
16. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.
Raffi F; Jaeger H; Quiros-Roldan E; Albrecht H; Belonosova E; Gatell JM; Baril JG; Domingo P; Brennan C; Almond S; Min S;
Lancet Infect Dis; 2013 Nov; 13(11):927-35. PubMed ID: 24074642
[TBL] [Abstract][Full Text] [Related]
17. Phase 2a randomized controlled trial of short-term activity, safety, and pharmacokinetics of a novel nonnucleoside reverse transcriptase inhibitor, RDEA806, in HIV-1-positive, antiretroviral-naive subjects.
Moyle G; Boffito M; Stoehr A; Rieger A; Shen Z; Manhard K; Sheedy B; Hingorani V; Raney A; Nguyen M; Nguyen T; Ong V; Yeh LT; Quart B
Antimicrob Agents Chemother; 2010 Aug; 54(8):3170-8. PubMed ID: 20498326
[TBL] [Abstract][Full Text] [Related]
18. Raltegravir (MK-0518): an integrase inhibitor for the treatment of HIV-1.
Evering TH; Markowitz M
Drugs Today (Barc); 2007 Dec; 43(12):865-77. PubMed ID: 18174972
[TBL] [Abstract][Full Text] [Related]
19. Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study.
Akil B; Blick G; Hagins DP; Ramgopal MN; Richmond GJ; Samuel RM; Givens N; Vavro C; Song IH; Wynne B; Ait-Khaled M;
Antivir Ther; 2015; 20(3):343-8. PubMed ID: 25321146
[TBL] [Abstract][Full Text] [Related]
20. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults.
Min S; Sloan L; DeJesus E; Hawkins T; McCurdy L; Song I; Stroder R; Chen S; Underwood M; Fujiwara T; Piscitelli S; Lalezari J
AIDS; 2011 Sep; 25(14):1737-45. PubMed ID: 21716073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
